Brookline Capital Management Predicts CRBU FY2026 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities researchers at Brookline Capital Management decreased their FY2026 EPS estimates for Caribou Biosciences in a research report issued to clients and investors on Monday, November 3rd. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of ($0.99) for the year, down from their prior estimate of ($0.97). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ FY2027 earnings at ($1.46) EPS, FY2028 earnings at ($2.09) EPS and FY2029 earnings at ($3.80) EPS.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%. The company had revenue of $2.67 million during the quarter, compared to analyst estimates of $1.64 million.

Several other equities research analysts have also issued reports on CRBU. Wall Street Zen raised Caribou Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 24th. Citigroup lifted their price target on Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, October 8th. HC Wainwright lifted their target price on shares of Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Truist Financial set a $7.00 target price on shares of Caribou Biosciences in a research report on Tuesday. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.75.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU opened at $2.17 on Wednesday. The firm has a fifty day moving average price of $2.20 and a two-hundred day moving average price of $1.68. Caribou Biosciences has a one year low of $0.66 and a one year high of $3.54. The company has a market cap of $202.08 million, a price-to-earnings ratio of -1.22 and a beta of 2.59.

Institutional Investors Weigh In On Caribou Biosciences

A number of hedge funds have recently made changes to their positions in CRBU. CWM LLC lifted its stake in Caribou Biosciences by 53.5% in the second quarter. CWM LLC now owns 33,839 shares of the company’s stock worth $43,000 after purchasing an additional 11,798 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in Caribou Biosciences by 69.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 40,813 shares of the company’s stock worth $51,000 after purchasing an additional 16,736 shares during the last quarter. Liberty Wealth Management LLC bought a new stake in Caribou Biosciences in the third quarter worth $45,000. Next Capital Management LLC bought a new stake in shares of Caribou Biosciences in the 2nd quarter valued at about $25,000. Finally, Nelson Capital Management LLC lifted its stake in shares of Caribou Biosciences by 31.1% in the 1st quarter. Nelson Capital Management LLC now owns 85,020 shares of the company’s stock valued at $78,000 after acquiring an additional 20,162 shares during the last quarter. 77.51% of the stock is currently owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.